227 related articles for article (PubMed ID: 22332910)
1. Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease.
Miller BR; Dorner JL; Bunner KD; Gaither TW; Klein EL; Barton SJ; Rebec GV
J Neurochem; 2012 May; 121(4):629-38. PubMed ID: 22332910
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.
Miller BR; Dorner JL; Shou M; Sari Y; Barton SJ; Sengelaub DR; Kennedy RT; Rebec GV
Neuroscience; 2008 Apr; 153(1):329-37. PubMed ID: 18353560
[TBL] [Abstract][Full Text] [Related]
3. Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.
Dorner JL; Miller BR; Klein EL; Murphy-Nakhnikian A; Andrews RL; Barton SJ; Rebec GV
Brain Res; 2009 Sep; 1290():111-20. PubMed ID: 19616518
[TBL] [Abstract][Full Text] [Related]
4. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease.
Sari Y; Prieto AL; Barton SJ; Miller BR; Rebec GV
J Biomed Sci; 2010 Jul; 17(1):62. PubMed ID: 20663216
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.
Rebec GV
Antioxid Redox Signal; 2013 Dec; 19(17):2115-28. PubMed ID: 23642110
[TBL] [Abstract][Full Text] [Related]
6. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.
Rebec GV; Conroy SK; Barton SJ
Neuroscience; 2006; 137(1):327-36. PubMed ID: 16257492
[TBL] [Abstract][Full Text] [Related]
7. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
Petr GT; Schultheis LA; Hussey KC; Sun Y; Dubinsky JM; Aoki C; Rosenberg PA
Eur J Neurosci; 2013 Aug; 38(3):2477-90. PubMed ID: 23586612
[TBL] [Abstract][Full Text] [Related]
9. Extracellular ascorbate modulates cortically evoked glutamate dynamics in rat striatum.
Rebec GV; Witowski SR; Sandstrom MI; Rostand RD; Kennedy RT
Neurosci Lett; 2005 Apr; 378(3):166-70. PubMed ID: 15781152
[TBL] [Abstract][Full Text] [Related]
10. Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice.
Jiang R; Diaz-Castro B; Looger LL; Khakh BS
J Neurosci; 2016 Mar; 36(12):3453-70. PubMed ID: 27013675
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.
Ortiz AN; Kurth BJ; Osterhaus GL; Johnson MA
J Neurochem; 2010 Feb; 112(3):755-61. PubMed ID: 19929911
[TBL] [Abstract][Full Text] [Related]
12. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
[TBL] [Abstract][Full Text] [Related]
13. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
14. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.
Nicniocaill B; Haraldsson B; Hansson O; O'Connor WT; Brundin P
Eur J Neurosci; 2001 Jan; 13(1):206-10. PubMed ID: 11135020
[TBL] [Abstract][Full Text] [Related]
15. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.
Liévens JC; Woodman B; Mahal A; Spasic-Boscovic O; Samuel D; Kerkerian-Le Goff L; Bates GP
Neurobiol Dis; 2001 Oct; 8(5):807-21. PubMed ID: 11592850
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
Rebec GV; Barton SJ; Ennis MD
J Neurosci; 2002 Jan; 22(2):RC202. PubMed ID: 11784814
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
[TBL] [Abstract][Full Text] [Related]
18. Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum.
Vetter JM; Jehle T; Heinemeyer J; Franz P; Behrens PF; Jackisch R; Landwehrmeyer GB; Feuerstein TJ
J Neurochem; 2003 May; 85(4):1054-63. PubMed ID: 12716437
[TBL] [Abstract][Full Text] [Related]
19. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
[TBL] [Abstract][Full Text] [Related]
20. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
